Memories: Ditching De Novo Discovery
This article was originally published in Start Up
Executive Summary
Drug development start-ups like Sention and David Pharmaceuticals are hoping to eliminate or reduce the safety risk inherent in drug development by identifying compounds Big Pharma has shelved or incorporated into marketed drugs and which are thought to be safe in humans. Instead of starting from scratch with de novo discovery of new molecules, they are focusing on in-licensing either promising compounds or marketed products that could benefit from incremental improvements.You may also be interested in...
Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis
The recent setback in SUI by Lilly's depression drug duloxetine may have implcations for a handful of biotech companies aiming to exploit their knowledge of the brain-gut axis to develop CNS drugs for IBS, OAB and other below-the-belt indications. Dynogen and Vela are two companies with promising products in the area.
Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis
The recent setback in SUI by Lilly's depression drug duloxetine may have implcations for a handful of biotech companies aiming to exploit their knowledge of the brain-gut axis to develop CNS drugs for IBS, OAB and other below-the-belt indications. Dynogen and Vela are two companies with promising products in the area.
Goodbye, Blue Sky: Shortcutting Discovery
A handful of European biotechnology companies is embracing development shortcuts that were once the exclusive provenance of specialty pharmaceutical firms. Shedding traditional biotech start-up discovery models, these firms aim to identify, reformulate and incrementally improve existing products. The hope is that low risk needn't be low reward; in the process these so-called reprofilers of existing therapies may indeed spark an increase in industry productivity. The trick, observers say, is finding and getting their hands on the right products.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports